Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
AstraZeneca
Sotio Biotech Inc.
National Cancer Institute (NCI)
Neonc Technologies, Inc.
Radiopharm Theranostics, Ltd
MacroGenics
MacroGenics
ImmunityBio, Inc.
GV20 Therapeutics
DualityBio Inc.
Incyte Corporation
OncoHost Ltd.
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Hoffmann-La Roche
Incyte Corporation
University of Virginia
Incyte Corporation
Marengo Therapeutics, Inc.
British Columbia Cancer Agency
NRG Oncology
OncoC4, Inc.
Theratechnologies
SOLTI Breast Cancer Research Group
Stanford University
Seagen Inc.
National Cancer Institute (NCI)
AstraZeneca
Salubris Biotherapeutics Inc
Pfizer
Xencor, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Pfizer
Exelixis
Memorial Sloan Kettering Cancer Center
University of Florida
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Jules Bordet Institute
Xencor, Inc.
Incyte Corporation
Opna Bio LLC
Genocea Biosciences, Inc.